IceCure Medical Ltd
ICCMHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, IceCure Medical Ltd focuses on Medical Devices services and products. IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the. Valued at $7.6M, ICCM is a micro-cap name in its sector. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Market Cap
$7.6M
Beta
0.45
P/E (TTM)
—
P/E (Fwd)
-0.67
EPS (TTM)
$-6.78
EPS (Fwd)
$-3.31
ROE
-228.3%
ROA
-73.9%
Cash
$12.0M
Total Debt
$90,000
Free CF
-$9.5M
52W Change
-92.8%
Annual Financials
Cash vs Debt
Where ICCM stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ICCM finished 74.83% below its 150-day moving average ($8.98) and 80.81% below its 200-day moving average ($11.78). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ICCM overbought or oversold?
At the September 3, 2026 close, ICCM's RSI(14) was 6.0, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $12.0M in cash comfortably exceeding the $90K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$9.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -228.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $3.1M (2022) to $3.4M (2025).
With a beta below 0.7, IceCure Medical Ltd typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for IceCure Medical Ltd and its sector.